Table a1 Univariate analysis of factors influencing death from prostate cancer in men with clinically localised prostate cancer, (a) and given no initial treatment: N=1663 and (b) initially treated with hormones: N=670
From: Long-term outcome among men with conservatively treated localised prostate cancer
Variable | N (%) | Hazard ratio (95% CI) | Prostate cancer death at 10 years (%) |
|---|---|---|---|
(a) | |||
Gleason score a | |||
⩽5 | 57 (3) | 0.59 (0.2–1.9) | 6 |
6 | 589 (35) | 1b | 10 |
7 | 313 (19) | 2.24 (1.5–3.3) | 23 |
8 | 136 (8) | 3.84 (2.5–5.9) | 38 |
9 or 10 | 81 (5) | 8.64 (5.7–13.2) | 53 |
Unassignedc | 487(29) | 2.39 (1.7–3.4) | 24 |
χ2 (trend)=101 | |||
Serum PSA (ng ml−1) | |||
⩽4 | 513 (31) | 1b | 12 |
>4–10 | 416 (25) | 1.14 (0.8–1.7) | 15 |
>10–25 | 432 (26) | 2.13 (1.5–3) | 27 |
>25–50 | 212 (13) | 2.64 (1.8–3.9) | 30 |
>50–100 | 90 (5) | 4.1 (2.6–6.3) | 41 |
χ 2(trend)=56 | |||
Clinical stage | |||
T1 | 435 (26) | 0.42 (0.3–0.6) | 10 |
T2 | 395 (24) | 1b | 22 |
T3 | 126 (8) | 1.69 (1.1–2.5) | 33 |
Txc | 707 (43) | 1.02 (0.8–1.4) | 24 |
χ 2(trend)=21 | |||
Cancer in biopsy (%) | |||
⩽6 | 315 (19) | 1b | 10 |
>6–20 | 308 (19) | 1.16 (0.7–2) | 10 |
>20–40 | 196 (12) | 2.75 (1.7–4.5) | 27 |
>40–75 | 202 (12) | 3.73 (2.3–6) | 29 |
>75–100 | 156 (9) | 4.3 (2.6–7) | 33 |
Unspecifiedc | 486 (29) | 2.58 (1.7–4) | 24 |
χ2=59 | |||
Age (years) | |||
⩽65 | 357 (21) | 0.7 (0.5–1) | 14 |
>65–70 | 466 (28) | 1b | 18 |
>70–73 | 417 (25) | 1.23 (0.9–1.7) | 22 |
>73–76 | 423 (25) | 1.6 (1.2–2.2) | 28 |
χ2 (trend)=23 | |||
Year of diagnosis | |||
1990 | 46 (3) | 1.68 (0.9–3.2) | 29 |
1991 | 86 (5) | 1.73 (1.1–2.8) | 30 |
1992 | 168 (10) | 1.71 (1.1–2.6) | 25 |
1993 | 266 (16) | 1.27 (0.8–1.9) | 22 |
1994 | 344 (21) | 1.1 (0.7–1.7) | 18 |
1995 | 370 (22) | 0.97 (0.6–1.5) | 15 |
1996 | 383 (23) | 1b | (not yet achieved) |
χ2 (trend)=11 | |||
Method of diagnosis | |||
Needle biopsy | 611 (37) | 1b | 23 |
TURP | 1023 (61) | 0.83 (0.7–1.1) | 19 |
Unspecifiedc | 29 (2) | 0.9 (0.4–2.2) | 19 |
χ2=1.9 | |||
(b) | |||
Gleason score reviewed a | |||
⩽5 | 4 (1) | 1.30 (0.2–9.7) | — |
6 | 92 (14) | 1b | 39 |
7 | 187 (28) | 1.28 (0.8–2.1) | 40 |
8 | 114 (17) | 1.92 (1.1–3.2) | 46 |
9 or 10 | 83 (12) | 3.82 (2.3–6.4) | 68 |
Unassignedc | 190 (28) | 1.78 (1.1–2.9) | 48 |
χ2 (trend)=33 | |||
Serum PSA (ng ml−1) | |||
⩽4 | 33 (5) | 1b | 36 |
>4–10 | 86 (13) | 1.03 (0.5–2.2) | 40 |
>10–25 | 175 (26) | 0.79 (0.4–1.6) | 32 |
>25–50 | 188 (28) | 1.42 (0.7–2.8) | 48 |
>50–100 | 188 (28) | 1.95(1–3.9) | 62 |
χ2 (trend)=20 | |||
Clinical stage | |||
T1 | 71 (11) | 0.7 (0.4–1.2) | 34 |
T2 | 217 (32) | 1b | 44 |
T3 | 143 (21) | 1.32 (0.9–1.9) | 46 |
Txc | 239 (36) | 1.04 (0.8–1.4) | 51 |
χ2(trend)=2 | |||
Cancer in biopsy (%) | |||
⩽6 | 26 (4) | 1b | 33 |
>6–20 | 78 (12) | 1.13 (0.5–2.6) | 40 |
>20–40 | 82 (12) | 1.41 (0.6–3.2) | 44 |
>40–75 | 134 (20) | 1.28 (0.6–2.9) | 40 |
>75–100 | 157 (23) | 1.87 (0.9–4.1) | 53 |
Unspecifiedc | 193 (29) | 1.56 (0.7–3.4) | 48 |
χ2=5.8 | |||
Age (years) | |||
⩽65 | 117 (18) | 0.88 (0.6–1.3) | 42 |
>65–70 | 199 (30) | 1b | 42 |
>70–73 | 177 (26) | 1.0 (0.7–1.4) | 46 |
>73–76 | 177 (26) | 1.24 (0.9–1.7) | 54 |
χ2(trend)=2.8 | |||
Year of diagnosis | |||
1990 | 8 (1) | 0.65 (0.2–2.1) | 25 |
1991 | 23 (3) | 1.18 (0.6–2.3) | 40 |
1992 | 57 (9) | 1.39 (0.9–2.3) | 53 |
1993 | 80 (12) | 1.75 (1.2–2.6) | 63 |
1994 | 127 (19) | 1.08 (0.7–1.6) | 41 |
1995 | 181 (27) | 1.16 (0.8–1.7) | 40 |
1996 | 194 (29) | 1b | (not yet achieved) |
χ2(trend)=1.7 | |||
Method of diagnosis | |||
Needle biopsy | 428 (64) | 1b | 42 |
TURP | 232 (35) | 1.37 (1.1–1.8) | 52 |
Unspecifiedc | 10 (1) | 1.26 (0.5–3.1) | 50 |
χ2=4.8 | |||
